Welcome to the ACR/ARP Abstracts Website
There are several ways to explore this site:
- Browse 2020 abstracts in numerical order.
- Browse 2020 abstracts by viewing the list of session titles.
- View abstracts about a certain topic by visiting the keyword index.
- Search this site for a specific abstract.
- Access the meetings archive to view abstracts from previous meetings.
- Register or log in to save favorites.
Recent Meetings
2020 Late-Breaking Abstracts
- Abstract Number: L01
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study - Abstract Number: L02
Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study - Abstract Number: L03
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial - Abstract Number: L04
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - Abstract Number: L05
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic - Abstract Number: L06
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis - Abstract Number: L07
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial - Abstract Number: L08
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) - Abstract Number: L09
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA) - Abstract Number: L10
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734 - Abstract Number: L11
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study